IHU ICAN creates a new platform entirely dedicated to the processing and analysis of health data: ICAN I/O

IHU ICAN creates a new platform entirely dedicated to the processing and analysis of health data: ICAN I/O

Identification of disease risk factors, assistance with diagnosis, choice and monitoring of treatment effectiveness or monitoring of patient trajectories… Today, data is generated massively in many scientific and medical fields. These data are grouped under the name “Big Data”. With Big Data, mathematical modelling, statistics and IT are becoming essential tools for managing and analyzing this massive information. The resulting new information profoundly transforms our approach to physiopathology and the underlying biological mechanisms. To meet the new challenge of Big Data, the IHU ICAN has created a dedicated platform: ICAN Intelligence and Omics (I/O).

The expertise of the ICAN Intelligence and Omics (I/O) platform brings together the three essential bricks for carrying out projects around Big Data in health: 1- Data governance 2- Data collection and data management 3- Analysis and integration of multi-omics and clinical data.

The creation of this new platform is thus an answer to the evolution of modern technologies and the use of robust algorithms to meet the needs of researchers through a collaborative and holistic approach integrating multi-omics technologies and statistical analysis. ICAN Intelligence and Omics (I/O) provides its expertise to structure, collect and manage the large amount of data generated within the framework of research projects. Extraction, analysis and large-scale processing of unstructured, heterogeneous and often compartmentalized data from different stakeholders in research projects are part of the expertise of the ICAN Intelligence and Omics platform. The use of data, their circulation, processing, sharing, induces major challenges that the IHU ICAN tackles with the creation of this platform: that of the confidentiality of patient data, and the absence, to date, of mechanisms to standardize data transfer at European and international level.

The IHU ICAN has been addressing the issue of data for several months now, notably through the implementation of major research projects, such as Maestria, and relies on complete and secure management of the entire data “chain”, by structuring data collection thanks to a person dedicated to data governance, 2 data managers to collect, extract and classify the data collected and a data scientist to analyze them. The expertise of the ICAN Intelligence and Omics platform is backed by the legal department to answer regulatory questions.

The IHU ICAN is therefore positioned as a major international player capable of generating massive health data and, above all, of analyzing it and extracting the necessary knowledge in order to gain a better understanding of biology and thus contribute to improving public health.

The ICAN Intelligence and Omics (I/O) platform thus offers a service adapted for both academic and industrial research.

New Scientific Advisory Board for the IHU

New Scientific Advisory Board for the IHU ICAN

At the December 16, 2021 Board of Directors meeting, ICAN announced the composition of its new Scientific Advisory Board . ICAN has a prestigious SAB (Scientific Advisory Board) which has grown from 4 to 5 members in order to strengthen international scientific collaborations and to cover the main fields of interest of the IHU.

Composed of personalities recognized by the international scientific community in the field of cardiometabolism and nutrition, the SAB participates in the definition of ICAN’s scientific strategy and evaluates its scientific performance. It therefore plays a very important role in the scientific trajectory of ICAN.

Members of the SAB:

New Members

Pr André Carpentier

Scientific Director of the CHUS Research Centre

Professor at the Canadian Research Chair in Molecular Imaging of Diabetes

Department of Medicine

Sherbrooke University – Canada


Prof. Michael RODEN,

Director of the German Diabetes Center (DDZ), Professor of Endocrinology and Metabolic Diseases – Heinrich Heine University Düsseldorf

Director of the Division of Endocrinology and Diabetology at the University Hospital Düsseldorf



Pr Karin Sipido

Professor of Medicine and Head of Experimental Cardiology at the University of Leuven

Editor-in-Chief of Cardiovascular Research since January 2013


Renewed members

Pr Arnold von Eckardstein

Director of the Institute of Clinical Chemistry, Presidency POCT Commission, Medical Diagnostic Department

Co-Director, University Centre for Laboratory Medicine and Pathology – UZL



Professor Rozemarijn Vliegenthart

Radiologist and professor of cardiothoracic imaging at the University Medical Center of Groningen

The Netherlands.

Laurence Comte-Arassus joins the IHU-ICAN Board of Directors

Laurence Comte-Arassus joins the IHU-ICAN Board of Directors

Laurence Comte-Arassus, member of the board of directors and of the office of Snitem (National union of the medical technology industry) will participate this Thursday, June 24 for the first time in the board of directors of the IHU-ICAN (Institut hospitalo -academic of cardiometabolism and nutrition) as a qualified personality from the economic world.

Laurence Comte-Arassus was appointed to the IHU-ICAN Board of Directors last March. His appointment by the current board of directors reflects IHU-ICAN’s desire to strengthen its links with medical device companies. This university hospital institute, located in the heart of the Pitié-Salpêtrière hospital, relies on the medical and scientific excellence, in the field of cardiometabolic diseases, of the doctors and researchers of the AP-HP, the ‘Inserm and Sorbonne University. It is thus continuing its in-depth transformation to develop more public/private collaborations with a view to accelerating innovations for the benefit of patients suffering from cardiometabolic and nutritional pathologies.

The perfect knowledge of the medical device industry acquired during a remarkable professional career and her role within the Snitem will allow Laurence Comte-Arassus to bring a new dimension to the construction of the partnership policy of the IHU- I CAN.

Course of Laurence Comte-Arassus

Laurence Comte-Arassus joined GE Healthcare in February 2021, as General Manager of the France, Belgium, Luxembourg and French-speaking Africa (FBFA) zone after 26 years of experience in the technology and medical sector. She previously held the position of President of Medtronic France. She is also a member of several health think tanks.

About Snitem

Created in 1987, the National Union of the Medical Technology Industry (Snitem) brings together players in the medical technology and device industry, including companies involved in digital health. It federates more than 525 French or international companies, most of which are of the size of SMEs or ETIs. The Snitem is thus the first organization in France representing companies in this sector of activity and the privileged and referent interlocutor of the Public Authorities.

Download the press release